Companies agree to pay $110M settlement for PFAS chemicals in Ohio
The Chemours Co. (CC) said Wednesday it reached a settlement with the State of Ohio along with DuPont de Nemours Inc. (DD) and Corteva Inc. (CTVA) for $110 million to resolve claims related to the manufacture and sale of per- and polyfluoroalkyl substances (PFAS). The agreement resolves Ohio's PFAS claims from the companies' facilities including the Washington Works plant along the Ohio-West Virginia border. Chemours will pay 50% of the settlement costs, or $55 million, while DuPont and Corteva will be responsible for the remaining 50%. "Chemours believes this settlement furthers its objective to manage and resolve legacy liabilities," the company said. Chemours stock was up by 1.4% in premarket trading. DuPont's stock has risen 3.4% so far in 2023, compared to an 18.6% increase by the S&P 500 .
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-29-23 0715ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations